SCHEMBL716169

SCHEMBL716169

NC(=O)Nc1cccc(Nc2nccs2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.56
RAB9A P51151 7/20 0.56
LMNA P02545 5/20 0.56
MAPT P10636 3/20 0.56
ALDH1A1 P00352 3/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
KCNK3 O14649 1/20 0.54
KCNK9 Q9NPC2 1/20 0.54
AURKA O14965 2/20 0.52
PIM1 P11309 1/20 0.52
CDK2 P24941 1/20 0.52
GSK3B P49841 1/20 0.52
NPSR1 Q6W5P4 2/20 0.50
PLA2G7 Q13093 1/20 0.48
AURKB Q96GD4 1/20 0.47
RECQL P46063 2/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
GAA P10253 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL715540 0.88 KCNK3 (0.58) NPC1RAB9ALMNAMAPTALDH1A1
SCHEMBL8906815 0.86 PLA2G7 (0.59) NPC1RAB9ALMNAMAPTALDH1A1
SCHEMBL5027656 0.82 KCNK3 (0.58) NPC1RAB9ALMNAMAPTALDH1A1
SCHEMBL5770847 0.82 ALDH1A1 (0.70) NPC1RAB9ALMNAMAPTALDH1A1
SCHEMBL9287381 0.79 KCNK3 (0.61) NPC1RAB9ALMNAMAPTALDH1A1
SCHEMBL715948 0.78 PLA2G7 (0.52) NPC1RAB9ALMNAMAPTALDH1A1
SCHEMBL3042388 0.78 MBD2 (0.55) NPC1RAB9ALMNAMAPTALDH1A1
SCHEMBL715947 0.78 KCNK3 (0.56) NPC1RAB9ALMNAMAPTALDH1A1
SCHEMBL27675533 0.78 PLA2G7 (0.49) NPC1RAB9ALMNAMAPTALDH1A1
SCHEMBL352731 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993573-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2015-03-31 US disclosed
US-8835435-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2014-09-16 US disclosed
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS AB SCIENCE (FR) 2014-03-27 US disclosed
US-8450302-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2013-05-28 US disclosed
US-20120053186-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2012-03-01 US disclosed
US-20110201620-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2011-08-18 US disclosed
US-20080255141-A1 Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders AB SCIENCE 2008-10-16 US disclosed
US-7423055-B2 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. AB SCIENCE (FR) 2008-09-09 US disclosed
US-20080146585-A1 Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy AB SCIENCE 2008-06-19 US disclosed
US-20080004279-A1 Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases AB SCIENCE (FR) 2008-01-03 US disclosed
WO-2005102455-A1 USE OF C-KIT INHIBITORS FOR TREATING PLASMODIUM RELATED DISEASES AB SCIENCE (FR) 2005-11-03 WO disclosed
WO-2005102346-A2 USE OF C-KIT INHIBITORS FOR TREATING FIBROSIS AB SCIENCE (FR) 2005-11-03 WO disclosed
WO-2005102318-A1 USE OF C-KIT INHIBITORS FOR TREATING HIV RELATED DISEASES AB SCIENCE (FR) 2005-11-03 WO disclosed
WO-2005102325-A1 USE OF C-KIT INHIBITORS FOR TREATING INFLAMMATORY MUSCLE DISORDERS INCLUDING MYOSITIS AND MUSCULAR DYSTROPHY AB SCIENCE (FR) 2005-11-03 WO disclosed
WO-2005102326-A2 USE OF C-KIT INHIBITORS FOR TREATING RENAL DISEASES AB SCIENCE (FR) 2005-11-03 WO disclosed
US-20050239852-A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2005-10-27 US disclosed
EP-1525200-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB Science (FR) 2005-04-27 EP disclosed
WO-2004096225-A2 USE OF TYROSINE KINASE INHIBITORS FOR TREATING CEREBRAL ISCHEMIA AB SCIENCE (FR) 2004-11-11 WO disclosed
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. AB SCIENCE 2004-06-10 US disclosed
WO-2004014903-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146585-A1 Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy KIT, CPA3, CMA1 NPC1 3122/4885RAB9A 1796/4885LMNA 803/4885
US-20120053186-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS KIT, CHUK, MAP3K2 NPC1 2100/4885RAB9A 1947/4885LMNA 2891/4885
US-20110201620-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS KIT, ABL1, MUSK NPC1 4626/4885RAB9A 599/4885LMNA 1980/4885
US-20080004279-A1 Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases KIT, JAK3, MAP3K3 NPC1 3470/4885RAB9A 1366/4885LMNA 1978/4885
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. KIT, MAP3K2, CMA1 NPC1 2227/4885RAB9A 2337/4885LMNA 2342/4885
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS KIT, CHUK, CKS1B NPC1 2356/4885RAB9A 1773/4885LMNA 2982/4885
US-20050239852-A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors KIT, CHUK, MAP3K2 NPC1 2045/4885RAB9A 1962/4885LMNA 2799/4885
US-20080255141-A1 Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders KIT, MAP3K1, MAP3K6 NPC1 3150/4885RAB9A 3051/4885LMNA 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.